$TBPMF News

Last published 3y ago

3y agoTBPMFREDUVO™ Marketing Approval on the Right PathPR NewswireSecond Clarifax received from Health Canada.MONTREAL, Dec. 22, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug
3y agoTBPMFTetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with FavipiravirPR NewswireThe combination of ARDS-003 and Favipiravir presents viable treatments against viral infections. Results from the PIONEER clinical trial shows Favipiravir may improve severe COVID-19 recovery and ventilator-free survival
3y agoTBPMFTetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003PR NewswireTetra strengthens its intellectual property position with PCT and provisional patent applications for its innovative therapeutic, ARDS-003. MONTREAL, Nov. 29, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or
3y agoTBPMFTetra Bio-Pharma Provides Update on Its REDUVO™ New Drug SubmissionPR NewswireMONTREAL, Nov. 18, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its
4y agoTBPMFTetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue OceanPR NewswireOTTAWA, ON, Oct. 27, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that
4y agoTBPMFTetra and Prepaire Jointly Apply to BARDA for FundingPR NewswireCompanies jointly submitted a $750,000 USD application to BARDA to use Prepaire™ Shield discovery platform to assess repurposed drugs combined with onternabez as Chemical Threat Medical Countermeasures.Partnership
4y agoTBPMFTetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue OceanPR NewswireOTTAWA, ON, Sept. 8, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has revised the terms of its pr
4y agoTBPMFTetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 PatientsPR NewswireTetra and Cellvera to jointly develop an orally administered treatment, ARDS-003, in combination with the proven broad-spectrum antiviral, Qifenda 400MG (Favipiravir) Companies will jointly develop a combination therapeutic candidate for rapid clearanc
4y agoTBPMFTetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue OceanPR NewswireOTTAWA, ON, Aug. 11, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that it has entered into a subscription agreemen
4y agoTBPMFTetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral InfectionsPR NewswireARDS-003 is a novel therapeutic for acute systemic inflammation and prevention of acute respiratory distress syndrome (ARDS). ARDS-003 may offer steroid-sparing opportunities. ARDS-003 has demonstrated antiviral properties. ARDS-003 developed as an o
4y agoAKAN TBPMFAkanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription DrugPR NewswireProvides Tetra with stable supply of high-quality ingredients and regulatory-approved services to satisfy clinical trials and prescription products Diversifies Akanda into cancer pain medical market as a specialized manufacturer of cannabis-based drug
4y agoAKAN TBPMF TSX:TBPAkanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription DrugBusiness WireProvides Tetra with stable supply of high-quality ingredients and regulatory-approved services to satisfy clinical trials and prescription products Diversifies Akanda into cancer pain medical market as a specialized manufacturer of cannabis-based dru
4y agoTBPMFTetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory UpdatePR NewswireOTTAWA, ON, June 6, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") ((TBP) ((TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announces the launch of its new wholly owned subsidiary 'Tetra Bio-Phar
4y agoTBPMFTetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special MeetingPR NewswireOTTAWA, ON, May 31, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, held its annual general and special meeting (the "Meeting") o
4y agoTBPMFTetra Bio-Pharma Appoints Chief Financial OfficerPR NewswireOTTAWA, ON, May 30, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is pleased to announce the appointment of Leslie Auld, H.BSc, MBA
4y agoTBPMFTetra Bio-Pharma Receives EMA Orphan Drug Designation for a Novel Topical Therapeutic Containing CBDPR NewswireNovel proprietary cannabidiol (CBD) therapeutic has been classified as an orphan medicinal product for the indication of epidermolysis bullosa (EB). Drug is ready for human clinical trials. OTTAWA, ON, May 18, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc
4y agoTBPMFTetra Bio-Pharma Announces Closing of First Tranche with CannvalatePR NewswireOTTAWA, ON, May 17, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of the first tranche of the p
4y agoTBPMFTetra Bio-Pharma Announces Licensing Agreement with True North for Patented CBD TechnologyPR NewswirePanag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag. Use of a highly innovative proprietary liposome encapsulated technology leads to a
4y agoTBPMFTetra Bio-Pharma and Cannvalate Enter Into PartnershipPR NewswireCannvalate to invest CAD$7.5M in Tetra. Cannvalate to launch and manage QIXLEEF™ and CAUMZ™ clinical trials in Australia. The Company to benefit from a 43.5% tax credit on all money spent on clinical trials in Australia. OTTAWA, ON, May 5, 2022
4y agoTBPMFTetra Bio-Pharma's QIXLEEF™ on Track After Type C Meeting with U.S. FDAPR NewswireThe Type C meeting with the FDA provides guidance to strengthen QIXLEEF™ nonclinical and toxicological data package for marketing approval. OTTAWA, ON, March 17, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTC
4y agoTBPMFTetra Bio-Pharma Provides Update on Research Collaboration with the University of Montreal Hospital Research Centre for Inhaled CBDPR NewswireHealth Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled CBD in healthy cannabinoid users. The collaboration with the CRCHUM will allow Tetra to obtain phase I clinical data on inhaled CBD.
4y agoTBPMF THRNTetra Bio-Pharma Signs License Agreement with Thorne for a Prebiotic Dietary SupplementPR NewswireOTTAWA, ON, Feb. 22, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, today announced it has signed a Licensing Agreement with Thorn
4y agoTBPMFTetra Bio-Pharma Receives $4.5M from the Ministère de l'Économie et de l'Innovation/Investissement QuébecPR NewswireMONTREAL, Feb. 16, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is proud to announce the approval of a $4.5M CDN participative lo
4y agoAVCNF TBPMFAvicanna Enters into a Strategic Partnership with Tetra Bio-PharmaGlobeNewswireTORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company") (TSX:AVCN) (OTCQX:AVCNF) (FSE: 0NN), an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commer
4y agoAVCNF TBPMFTetra Bio-Pharma Enters into a Strategic Partnership with AvicannaPR NewswireThe proposed partnership will encompass three potential strategic pillars across supply of API, commercialization of prescription products, and co-development of pharmaceutical drug candidates. OTTAWA, ON, Feb. 14, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("
4y agoTBPMFREPEAT – Tetra Bio-Pharma Announces Pricing of Marketed Public Offering of UnitsGlobeNewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OTTAWA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug
4y agoTBPMFTetra Bio-Pharma Announces Pricing of Marketed Public Offering of UnitsGlobeNewswireNOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OTTAWA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug
4y agoCAVR DIGP DSS PJET+6CEOs Presenting at the Emerging Growth Conference on December 8; Register NowGlobeNewswireMIAMI, Dec. 07, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets, announces the Schedule of the 21st Emer
4y agoTBPMFQIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation AerosolsPR NewswireTetra Bio-Pharma Confirms Meeting with the FDA to Align on the Requirements for Marketing Authorization OTTAWA, ON, Nov. 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cann
4y agoTBPMFTetra Bio-Pharma Announces Positive Initial Clinical Data from Both of its Ongoing Phase 2 Clinical Trials of QIXLEEF™PR NewswireOTTAWA, ON, Nov. 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced positive initial clinical data from its ongoin
5y agoTBPMFTetra Bio-Pharma Inc. Announces Termination of "At-The-Market" OfferingPR NewswireOTTAWA, ON, Nov. 4, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, announced today the termination of its previously announced "at-
5y agoTBPMFTetra Bio-Pharma Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines AgencyPR NewswireOTTAWA, ON, Oct. 21, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the European Medicines Agency (EMA) Commi
5y agoTBPMFTetra Bio-Pharma Provides Update on Clinical Development Program for QIXLEEF™PR NewswireOTTAWA, ON, Oct. 14, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achie
5y agoENVB FTSSF IEC TBPMF+1Proactive news headlines including Thesis Gold, IEC Electronics, Tetra Bio-Pharma and MydecineGlobeNewswireNew York, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Tetra Bio-Pharma (TSX:TBP, OTCQB:TBPMF) says its first ca
5y agoTBPMFREDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.PR NewswireTetra is gearing up to launch REDUVO™, its first cannabinoid-derived medicine, in Canada. REDUVO™ 5-year cumulative gross sales expected to reach $121M. The Company has started numerous pre-launch activities to prepare for the introduction of RE
5y agoTBPMFTetra Bio-Pharma Receives Positive Scientific Advice Assessment (SAA) Report for QIXLEEF™PR NewswireSAA Report endorsed Tetra Bio-Pharma's proposed nonclinical development and quality programs for QIXLEEF™. SAA Report provides clarity on clinical requirements for registration in Europe. OTTAWA, ON, Sept. 2, 2021 /PRNewswire/ - Tetra Bio-Pharm
5y agoTBPMFTetra Bio-Pharma Files PCT Patent Application for Cannabis Plant ResiduePR NewswireOTTAWA, ON, July 29, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc ("Tetra" or the Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis
5y agoTBPMFTetra Bio-Pharma Engages Christine Caron as Patient PartnerPR NewswireImportant step for Tetra to ensure meaningful collaboration and patient engagement in research. OTTAWA, ON, July 22, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") ((TBP) ((TBPMF) (FRA:JAM1), a leader in cannabinoid-derived
5y agoTBPMFTetra Bio-Pharma Accelerates REBORN1© TrialPR NewswireEthics Committee approves REBORN1© protocol amendment allowing for the addition of two immediate release oral opioids to be compared against QIXLEEF™. REBORN1© is the first of its kind proof-of-concept phase 2 study comparing a cannabinoid-based d
5y agoBLGO BUSXF CBDHF CYDY+14Proactive news headlines including GlobeX Data, GR Silver Mining, ME2C Environmental and Great Bear ResourcesGlobeNewswireNew York , June 21, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies: AIM ImmunoTech Inc (NYSEAMERICAN:AIM) completes Phase
5y agoTBPMFSignificant Discovery Reveals New Antiviral Properties of Tetra Bio-Pharma's Innovative Drug ARDS-003PR NewswireCombining ARDS-003 with antiviral drugs significantly decreased viral replication compared to antiviral treatment alone. OTTAWA, ON, June 21, 2021 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA: JAM1),
5y agoFUNFF TBPMF TRUFF SLHGNext Super Stocks on the Move: Tetra Bio-Pharma, Red Light Holland, FansUnite, and Skylight HealthGlobeNewswireNEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream inv
5y agoAGFAF AMYT BETRF BLONF+24Proactive news headlines including Sigma Lithium Resources, Royal Road Minerals, Western Magnesium and Marvel DiscoveryGlobeNewswireNew York , June 02, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Binovi Technologies Corp (CVE:VISN) (OTCQB:BNVIF
5y agoTBPMFHealth Canada Accepts New Drug Submission for REDUVO(TM) as a Treatment for Patients with Chemotherapy-induced Nausea and VomitingACCESS NewswireThis news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 The Company approaches a significant milestone advancing fr
5y agoALPP AMYZF ASWRF BLONF+21Proactive news headlines including Mountain Valley MD Holdings, Viscount Mining, CytoDyn and Gungnir ResourcesGlobeNewswireNew York, May 18, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCQB:
5y agoFUNFF HAPBF RQHTF TBPMFNEXT SUPER STOCKS on The Move: FansUnite, Reliq Health Tech, Hapbee, and Tetra Bio-PharmaGlobeNewswireNEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream inve
5y agoAMYZF AREC BLONF BTUMF+19Proactive news headlines including Q BioMed, Dalrada Corporation, Clean Air Metals and Evergold CorpGlobeNewswireNew York , May 11, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: CO2 GRO Inc (CVE:GROW) (OTCQB:BLONF) (FRA:4021) sells
5y agoTBPMFTetra Bio-Pharma Accelerates PLENITUDE(C) Clinical Trial to Evaluate the Effect of Cannabis for Use in Managing Uncontrolled Cancer PainACCESS NewswireFirst ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer QIXLEEF™ has the potential to transform the pain market OTTAWA, ON / ACCESSWIRE / May 11, 2021 / Tetra Bio-Ph
5y agoRYMDF TBPMF TRUFF VSQTFNEXT SUPER STOCKS on The Move: Tetra Bio-Pharma, Relay Medical, Victory Square Technologies, and Red Light HollandGlobeNewswireNEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream inve
5y agoABML AREC BKLLF BLONF+20Proactive news headlines including Binovi Technologies, Genprex, Esports Entertainment Group and Golden Minerals CompanyGlobeNewswireNew York, May 06, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies: Marvel Discovery Corp (CVE:MARV) (OTC:IMTFF) kicks o